Supira Medical Secures $120M Series E Funding Led by Novo Holdings and QIA for Next-Gen pVAD

Executive Evaluation

"We thank our existing investors for their continued trust and are honored to welcome new world-class investment institutions to join. This large-scale financing is a testament to the significant progress of the team, and we look forward to creating substantial value by improving clinical outcomes for HRPCI and cardiogenic shock patients."

---Nitin Salunke  President and CEO of Supira Medical

Interventional cardiac pump is a rapidly growingField, since Johnson & Johnson acquired Abiomed for $16.6 billion, this niche has entered a boom mode, with many innovative companies and products emerging both in China and internationally. For exampleMagenta Medical, Second Heart Assist, Procyrion, Fengkai Li Medical, Xin Qing, etc. These enterprise products each have their own characteristics, making the entireInterventional cardiac pumps have become more abundant.

However, currentlyIn the field of interventional cardiac pumps, Johnson & Johnson dominates the market. Most participants' products are still in clinical research, and it will take some time before they are commercially available.However, this market is very large and growing rapidly. Last year, Johnson & Johnson (Abiomed) Sales reached 1.496 billion USD, year-over-year+14.5%. Johnson & Johnson's sales all come from the older generation.Interventional Cardiac Pump.

New GenerationCurrently, all companies in the interventional cardiac pump field are at the same starting line (in clinical research), but relatively speaking, Johnson & Johnson still leads the competition by one or two years.Time. OverseasNew GenerationRepresentative products of interventional cardiac pumps include Johnson & Johnson's.Impella ECP、Magenta Medical's Elevate andSupira MedicalTheSupira pVADIn the future, the main competition in the U.S. market will also revolve around these three.

Supira pVADHas already received the FDA "Breakthrough Device Designation" and has also initiated clinical research in the United States (completed last year).EFS Clinical Enrollment）。

Supira pVAD

Supira pVADIs a new type of interventional cardiacPump, which incorporates many innovative elements in its design:

• Small Profile Design (10Fr)
  

Achieve Single ProGlide Suture Closure

Significantly Reduce the Risk of Vascular Complications

• Self-expanding aortic impeller + flexible cannula (expandable to 22Fr)

Enhance system stability and reduce hemolysis risk

• High Flow (5.5 Liters/Minute)

HR-PCI and Cardiogenic Shock (CS) Integrated Treatment Platform

• Rapid Exchange (0.018-inch Rapid Exchange (RX) Delivery System

Optimized Delivery Performance Design

• Integrated Aortic and Left Ventricle Pressure Sensors
  

Real-time "Decoupling" (Assistance Effect) Feedback During HR-PCI Procedure

The following isSupira pVADWith Johnson &Product Comparison of Magenta Medical (These Two Products Are Currently Representative of Interventional Pumps)